Table 1.

Mutation rates in patient tumor specimens available for analysis (N = 288)

GeneMutation rate, %Patients with mutations, nPatients with data available, nData completenessa, %
KRAS (codons 12, 13, and 61)4512427796
KRAS (codons 12 and 13)b4211728097
KRAS (codon 61)2728499
NRAS51428298
EGFR1328097
BRAF71824384
PTEN61527294
PIK3CA92425589
AKT1<1125087
TP536016727796
CTNNB12525689

NOTE: AKT1, v-akt murine thymoma viral oncogene homolog 1; BRAF, v-raf murine sarcoma viral oncogene homolog B1; CTNNB1, catenin (cadherin-associated protein), β-1, 88 kDa; KRAS, v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog; NRAS, neuroblastoma RAS viral oncogene homolog; PIK3CA, phosphoinositide-3-kinase, catalytic, α-polypeptide; PTEN, phosphatase and tensin homolog; TP53, tumor protein p53.

  • aFor each gene, data completeness assessed as the number of patients with data available divided by 288 (the number of patients with samples yielding results).

  • bData from a previous analysis of KRAS mutations (codons 12 and 13) using allele-specific polymerase chain reaction (DxS/Qiagen; ref. 1).